phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

ESMO 2025: VT3989 Continues to Show Promising Early Results in Patients with Advanced Mesothelioma

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

October 19, 2025


October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025

October 22 2025

October 21 2025

October 20 2025

October 19 2025

October 18 2025

October 17 2025

October 16 2025

October 15 2025

Angell Street Psychiatry
Copyright 2025 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy